PDS Biotechnology Corporation (PDSB) Dividend History

Company News

• PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  PDS Biotechnology Corporation announced that it granted 7,000 nonstatutory stock options to an employee as a material inducement to employment. The options have an exercise price of $2.25 and vest over a four-year period.

  GlobeNewswire Inc.
• PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

  PDS Biotech announced positive results from its Phase 2 IMMUNOCERV trial, showing a 36-month overall survival rate of 84.4% in locally advanced cervical cancer patients treated with Versamune® HPV and chemoradiation.

  GlobeNewswire Inc.
• PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

  PDS Biotechnology will present updated data from the VERSATILE-002 trial evaluating first-line treatment with Versamune® HPV in combination with KEYTRUDA® in patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma at the upcoming ESMO Congress 2024.

  GlobeNewswire Inc.

  Featured Companies: MRK
• PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

  30 month median overall survival (OS); median OS independent of patient CPS score

  GlobeNewswire Inc.
• PDS Biotechnology Announces Details of Virtual KOL Event

  Virtual Webinar Updated VERSATILE-002 Phase 2 Trial Results, Unmet Treatment Needs in Advanced Head and Neck Cancer and Planned Triple Combination Trial to be held May 8, 2024 Virtual Webinar Updated VERSATILE-002 Phase 2 Trial Results, Unmet Treatment Needs in Advanced Head and Neck Cancer and Planned Triple Combination Trial to be held May 8, 2024

  GlobeNewswire Inc.